Sintilimab and Chidamide for Refractory Transformed Diffuse Large B Cell Lymphoma: A Case Report and A Literature Review
Patients with relapsed/refractory (R/R) transformed diffused large B cell lymphoma (tDLBCL) have a poor prognosis and a low survival rate. In addition, no standard therapy has yet been established for R/R tDLBCL. Herein we presented a single case of a patient with R/R tDLBCL who was successfully tre...
Guardado en:
| Autores principales: | , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Frontiers Media S.A.
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/9a18cc86773d4bb3be23905569fb2808 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:9a18cc86773d4bb3be23905569fb2808 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:9a18cc86773d4bb3be23905569fb28082021-11-08T05:40:18ZSintilimab and Chidamide for Refractory Transformed Diffuse Large B Cell Lymphoma: A Case Report and A Literature Review2234-943X10.3389/fonc.2021.757403https://doaj.org/article/9a18cc86773d4bb3be23905569fb28082021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fonc.2021.757403/fullhttps://doaj.org/toc/2234-943XPatients with relapsed/refractory (R/R) transformed diffused large B cell lymphoma (tDLBCL) have a poor prognosis and a low survival rate. In addition, no standard therapy has yet been established for R/R tDLBCL. Herein we presented a single case of a patient with R/R tDLBCL who was successfully treated with sintilimab and chidamide. The patient was a 71-year-old man with pulmonary mucosa-associated lymphoid tissue lymphoma. He did not receive any treatment until tDLBCL was confirmed 2 years later. The tDLBCL was primary refractory to R2-CHOP, R2-MTX, and Gemox regimens. However, the patient achieved sustained complete remission after the combination therapy of sintilimab and chidamide. To the best of our knowledge, this is the first report of sintilimab combined with chidamide for the treatment of R/R tDLBCL, which opens up new therapeutic possibilities for this new combination therapy in future prospective clinical trials.Chao ChenWei ZhangDaobin ZhouYan ZhangFrontiers Media S.A.articleanti-PD-1HDAC inhibitortransformed diffuse large B cell lymphomahistologic transformationrefractoryNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENFrontiers in Oncology, Vol 11 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
anti-PD-1 HDAC inhibitor transformed diffuse large B cell lymphoma histologic transformation refractory Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 |
| spellingShingle |
anti-PD-1 HDAC inhibitor transformed diffuse large B cell lymphoma histologic transformation refractory Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Chao Chen Wei Zhang Daobin Zhou Yan Zhang Sintilimab and Chidamide for Refractory Transformed Diffuse Large B Cell Lymphoma: A Case Report and A Literature Review |
| description |
Patients with relapsed/refractory (R/R) transformed diffused large B cell lymphoma (tDLBCL) have a poor prognosis and a low survival rate. In addition, no standard therapy has yet been established for R/R tDLBCL. Herein we presented a single case of a patient with R/R tDLBCL who was successfully treated with sintilimab and chidamide. The patient was a 71-year-old man with pulmonary mucosa-associated lymphoid tissue lymphoma. He did not receive any treatment until tDLBCL was confirmed 2 years later. The tDLBCL was primary refractory to R2-CHOP, R2-MTX, and Gemox regimens. However, the patient achieved sustained complete remission after the combination therapy of sintilimab and chidamide. To the best of our knowledge, this is the first report of sintilimab combined with chidamide for the treatment of R/R tDLBCL, which opens up new therapeutic possibilities for this new combination therapy in future prospective clinical trials. |
| format |
article |
| author |
Chao Chen Wei Zhang Daobin Zhou Yan Zhang |
| author_facet |
Chao Chen Wei Zhang Daobin Zhou Yan Zhang |
| author_sort |
Chao Chen |
| title |
Sintilimab and Chidamide for Refractory Transformed Diffuse Large B Cell Lymphoma: A Case Report and A Literature Review |
| title_short |
Sintilimab and Chidamide for Refractory Transformed Diffuse Large B Cell Lymphoma: A Case Report and A Literature Review |
| title_full |
Sintilimab and Chidamide for Refractory Transformed Diffuse Large B Cell Lymphoma: A Case Report and A Literature Review |
| title_fullStr |
Sintilimab and Chidamide for Refractory Transformed Diffuse Large B Cell Lymphoma: A Case Report and A Literature Review |
| title_full_unstemmed |
Sintilimab and Chidamide for Refractory Transformed Diffuse Large B Cell Lymphoma: A Case Report and A Literature Review |
| title_sort |
sintilimab and chidamide for refractory transformed diffuse large b cell lymphoma: a case report and a literature review |
| publisher |
Frontiers Media S.A. |
| publishDate |
2021 |
| url |
https://doaj.org/article/9a18cc86773d4bb3be23905569fb2808 |
| work_keys_str_mv |
AT chaochen sintilimabandchidamideforrefractorytransformeddiffuselargebcelllymphomaacasereportandaliteraturereview AT weizhang sintilimabandchidamideforrefractorytransformeddiffuselargebcelllymphomaacasereportandaliteraturereview AT daobinzhou sintilimabandchidamideforrefractorytransformeddiffuselargebcelllymphomaacasereportandaliteraturereview AT yanzhang sintilimabandchidamideforrefractorytransformeddiffuselargebcelllymphomaacasereportandaliteraturereview |
| _version_ |
1718442930377588736 |